Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jan;41(1):17–23. doi: 10.1128/aac.41.1.17

Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.

R G Kansal 1, R Gomez-Flores 1, I Sinha 1, R T Mehta 1
PMCID: PMC163653  PMID: 8980748

Abstract

The therapeutic efficacy of liposomal clofazimine (L-CLF) against Mycobacterium avium complex (MAC) was evaluated in the acute and chronic infection models of the beige mouse (C57BL/6J bgj bgj). The maximum tolerated dose of L-CLF was inversely proportional to the infection level. L-CLF showed higher antibacterial activity than free clofazimine. Treatment with 25 mg of L-CLF per kg of body weight (intravenously) was started at days 1, 8, 15, and 22 postinfection and was studied at three levels of MAC infection (10(4), 10(5), and 10(6) bacilli/mouse). L-CLF treatment caused a significant (P < 0.05 to 0.001) reduction in the numbers of viable bacteria in lung, liver, and spleen at all infection levels, irrespective of time of treatment. However, the best results were obtained when an already established infection was treated (day 22). The organ-related differences in response to the treatment were also affected by the level of infection. A marked reduction in the numbers of CFU was observed in the lungs of mice with lower infection levels, whereas liver and spleen were treated more efficiently at higher infection levels. These studies might help in evaluations of host responses to therapy.

Full Text

The Full Text of this article is available as a PDF (255.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams D. I., Mitchell T. F., Child C. C., Shiboski S. C., Brosgart C. L., Mass M. M. Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis. 1993 Jun;167(6):1459–1463. doi: 10.1093/infdis/167.6.1459. [DOI] [PubMed] [Google Scholar]
  2. Alving C. R. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 1983;22(3):407–424. doi: 10.1016/0163-7258(83)90010-4. [DOI] [PubMed] [Google Scholar]
  3. Appelberg R., Castro A. G., Pedrosa J., Silva R. A., Orme I. M., Minóprio P. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun. 1994 Sep;62(9):3962–3971. doi: 10.1128/iai.62.9.3962-3971.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Appelberg R., Sarmento A., Castro A. G. Tumour necrosis factor-alpha (TNF-alpha) in the host resistance to mycobacteria of distinct virulence. Clin Exp Immunol. 1995 Aug;101(2):308–313. doi: 10.1111/j.1365-2249.1995.tb08356.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ausina V., Condom M. J., Mirelis B., Luquin M., Coll P., Prats G. In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrob Agents Chemother. 1986 May;29(5):951–952. doi: 10.1128/aac.29.5.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. BARRY V. C., BELTON J. G., CONALTY M. L., DENNENY J. M., EDWARD D. W., O'SULLIVAN J. F., TWOMEY D., WINDER F. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957 May 18;179(4568):1013–1015. doi: 10.1038/1791013a0. [DOI] [PubMed] [Google Scholar]
  7. Benson C. A. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. 1994 Apr;18 (Suppl 3):S237–S242. doi: 10.1093/clinids/18.supplement_3.s237. [DOI] [PubMed] [Google Scholar]
  8. Bermudez L. E., Martinelli J., Petrofsky M., Kolonoski P., Young L. S. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis. 1994 Mar;169(3):575–580. doi: 10.1093/infdis/169.3.575. [DOI] [PubMed] [Google Scholar]
  9. Bermudez L. E., Yau-Young A. O., Lin J. P., Cogger J., Young L. S. Treatment of disseminated Mycobacterium avium complex infection of beige mice with liposome-encapsulated aminoglycosides. J Infect Dis. 1990 Jun;161(6):1262–1268. doi: 10.1093/infdis/161.6.1262. [DOI] [PubMed] [Google Scholar]
  10. Bermudez L. E., Young L. S. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol. 1988 May 1;140(9):3006–3013. [PubMed] [Google Scholar]
  11. Bonventre P. F., Gregoriandis G. Killing of intraphagocytic Staphylococcus aureus by dihydrostreptomycin entrapped within liposomes. Antimicrob Agents Chemother. 1978 Jun;13(6):1049–1051. doi: 10.1128/aac.13.6.1049. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res Microbiol. 1994 Mar-Apr;145(3):197–206. doi: 10.1016/0923-2508(94)90018-3. [DOI] [PubMed] [Google Scholar]
  13. Düzgüneş N., Ashtekar D. R., Flasher D. L., Ghori N., Debs R. J., Friend D. S., Gangadharam P. R. Treatment of Mycobacterium avium-intracellulare complex infection in beige mice with free and liposome-encapsulated streptomycin: role of liposome type and duration of treatment. J Infect Dis. 1991 Jul;164(1):143–151. doi: 10.1093/infdis/164.1.143. [DOI] [PubMed] [Google Scholar]
  14. Ellner J. J., Goldberger M. J., Parenti D. M. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis. 1991 Jun;163(6):1326–1335. doi: 10.1093/infdis/163.6.1326. [DOI] [PubMed] [Google Scholar]
  15. Gangadharam P. R., Ashtekar D. A., Ghori N., Goldstein J. A., Debs R. J., Düzgünes N. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother. 1991 Sep;28(3):425–435. doi: 10.1093/jac/28.3.425. [DOI] [PubMed] [Google Scholar]
  16. Gangadharam P. R. Beige mouse model for Mycobacterium avium complex disease. Antimicrob Agents Chemother. 1995 Aug;39(8):1647–1654. doi: 10.1128/aac.39.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gangadharam P. R., Candler E. R. Activity of some antileprosy compounds against Mycobacterium intracellulare in vitro. Am Rev Respir Dis. 1977 Apr;115(4):705–708. doi: 10.1164/arrd.1977.115.4.705. [DOI] [PubMed] [Google Scholar]
  18. Horsburgh C. R., Jr, Selik R. M. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS). Am Rev Respir Dis. 1989 Jan;139(1):4–7. doi: 10.1164/ajrccm/139.1.4. [DOI] [PubMed] [Google Scholar]
  19. Klemens S. P., Cynamon M. H., Swenson C. E., Ginsberg R. S. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1990 Jun;34(6):967–970. doi: 10.1128/aac.34.6.967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Krajewska M. M., Anderson R., O'Sullivan J. F. Effects of clofazimine analogues and tumor necrosis factor-alpha individually and in combination on human polymorphonuclear leukocyte functions in vitro. Int J Immunopharmacol. 1993 Feb;15(2):99–111. doi: 10.1016/0192-0561(93)90086-e. [DOI] [PubMed] [Google Scholar]
  21. Le Conte P., Le Gallou F., Potel G., Struillou L., Baron D., Drugeon H. B. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob Agents Chemother. 1994 Dec;38(12):2695–2701. doi: 10.1128/aac.38.12.2695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lopez-Berestein G., Bodey G. P., Frankel L. S., Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987 Feb;5(2):310–317. doi: 10.1200/JCO.1987.5.2.310. [DOI] [PubMed] [Google Scholar]
  23. Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., Rosenblum M. G., Mehta R., Luna M., Hersh E. M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr;151(4):704–710. doi: 10.1093/infdis/151.4.704. [DOI] [PubMed] [Google Scholar]
  24. Macher A. M., Kovacs J. A., Gill V., Roberts G. D., Ames J., Park C. H., Straus S., Lane H. C., Parrillo J. E., Fauci A. S. Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med. 1983 Dec;99(6):782–785. doi: 10.7326/0003-4819-99-6-782. [DOI] [PubMed] [Google Scholar]
  25. Mehta R. T., Keyhani A., McQueen T. J., Rosenbaum B., Rolston K. V., Tarrand J. J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob Agents Chemother. 1993 Dec;37(12):2584–2587. doi: 10.1128/aac.37.12.2584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mehta R. T. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother. 1996 Aug;40(8):1893–1902. doi: 10.1128/aac.40.8.1893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Murray J. F., Felton C. P., Garay S. M., Gottlieb M. S., Hopewell P. C., Stover D. E., Teirstein A. S. Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop. N Engl J Med. 1984 Jun 21;310(25):1682–1688. doi: 10.1056/NEJM198406213102529. [DOI] [PubMed] [Google Scholar]
  28. Onyeji C. O., Nightingale C. H., Tessier P. R., Nicolau D. P., Bow L. M. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis. 1995 Sep;172(3):810–816. doi: 10.1093/infdis/172.3.810. [DOI] [PubMed] [Google Scholar]
  29. Peters J. H., Hamme K. J., Gordon G. R. Determination of clofazimine in plasma by high-performance liquid chromatography. J Chromatogr. 1982 May 14;229(2):503–508. doi: 10.1016/s0378-4347(00)84299-1. [DOI] [PubMed] [Google Scholar]
  30. Swenson C. E., Popescu M. C., Ginsberg R. S. Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol. 1988;15 (Suppl 1):S1–31. doi: 10.3109/10408418809104463. [DOI] [PubMed] [Google Scholar]
  31. Tomioka H., Saito H., Sato K., Yoneyama T. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):575–579. doi: 10.1164/ajrccm/144.3_Pt_1.575. [DOI] [PubMed] [Google Scholar]
  32. Young L. S., Inderlied C. B., Berlin O. G., Gottlieb M. S. Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis. 1986 Nov-Dec;8(6):1024–1033. doi: 10.1093/clinids/8.6.1024. [DOI] [PubMed] [Google Scholar]
  33. Young L. S. Mycobacterium avium complex infection. J Infect Dis. 1988 May;157(5):863–867. doi: 10.1093/infdis/157.5.863. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES